Evidence map›Paper›PMID 40199539›Full record

SynthesisNeurosciences (Riyadh, Saudi Arabia)2025

Risk factors for unexplained early neurological deterioration after intravenous thrombolysis: a meta-analysis.

J Li, C L Zhu, C Y Zhang, L M Li, R Liu, S Zhang, M L He

Abstract readMeta-Analysis
In one paragraph

Synthesis in Neurosciences (Riyadh, Saudi Arabia), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

J LiFrom The Neurology Department, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, China.
C L ZhuFrom The Neurology Department, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, China.
C Y ZhangFrom The Neurology Department, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, China.
L M LiFrom The Neurology Department, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, China.
R LiuFrom The Neurology Department, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, China.
S ZhangFrom The Neurology Department, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, China.
M L HeFrom The Neurology Department, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, China.ORCID https://orcid.org/0000-0002-1772-8183

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo explore the risk factors of unexplained early neurological dererioration (END) after IVT, and explore the underlying mechanisms by which these factors contribute to END onset and progression.

methodsWe performed a systematic literature search in accordance with PRISMA guidelines, utilizing PubMed, WOS, and EMBASE databases to identify all relevant studies investigating END in AIS patients who received IVT within 4.5 hours of symptom onset.

resultsOut of 2,613 reviewed records, 16 were included in this meta-analysis. The quantitative synthesis of data regarding the incidence of END in acute ischemic stroke (AIS) patients with IVT was 12% (95% confidence interval [CI], 10%-15%). Several factors were identified as significantly associated with post-IVT END, including demographic characteristics (age, male sex), comorbidities (hypertension, diabetes mellitus, atrial fibrillation), medications (antihypertensives, antiplatelets), admission parameters (hyperglycemia, elevated white blood cell count, cholesterol levels, blood pressure readings), timing of treatment, and the presence of large artery atherosclerosis (LAA).

conclusionUnderstanding and monitoring multiple factors associated with END, including other comorbidities, may achieve satisfactory results. The investigation of white blood cells' involvement in END following AIS merits particular attention, as it may guide the development of targeted preventive medications.

Indexed as

Fibrinolytic AgentsIschemic StrokeThrombolytic TherapyHumansMaleRisk FactorsFibrinolytic Agents

Identifiers

PMID40199539
PMCPMC11977583

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.